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BACKGROUND: Kim et al. report two patientswithmelanomametastases to the brain that responded to treatment with
RRx-001 andwhole brain radiotherapy (WBRT)without neurologic or systemic toxicity in the context of a phase I/II clinical
trial. RRx-001 is an reactive oxygen and reactive nitrogen species (ROS/RNS)-dependent systemically nontoxic hypoxic
cell radiosensitizerwith vascular normalizing properties under investigation in patientswith various solid tumors including
those with brain metastases. SIGNIFICANCE: Metastatic melanoma to the brain is historically associated with poor
outcomes and a median survival of 4 to 5 months. WBRT is a mainstay of treatment for patients with multiple brain
metastases, but no significant therapeutic advances for these patients have been described in the literature. To date,
candidate radiosensitizing agents have failed to demonstrate a survival benefit in patients with brain metastases, and in
particular, no agent has demonstrated improved outcome in patients with metastatic melanoma. Kim et al. report two
patients with melanomametastases to the brain that responded to treatment with novel radiosensitizing agent RRx-001
and WBRT without neurologic or systemic toxicity in the context of a phase I/II clinical trial.
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Brainmetastases are a common complication ofmelanoma and constitute a
significant cause of morbidity and mortality [1–3]. Their incidence in
melanoma is on the rise due to increased patient survival from improved
treatment options with targeted therapeutics (e.g., selective BRAF
inhibitors like vemurafenib or dabrafenib) and immune checkpoint
inhibitors (e.g., ipilimumab and nivolumab) [4–7]. In the setting of
disseminated disease, the goal of treatment is not necessarily to eradicate the
brain lesions but rather to control them, thereby conserving or prolonging
neurologic function, performance status, and potentially survival.
Associations between treatment of brain metastases and survival are
confounded by the high risk of death from progressive systemic
disease burden [8]. The impact on survival may, therefore, be more
easily assessable in terms of a neurologic versus nonneurologic cause
Table 1. Pertinent Studies with Immunotherapy, Chemotherapy, and/or Radiation in Melanoma Brain Metastases
Study Regimen Radiation
Therapy
Phase No. Patients Overall Intracranial
Response Rate %
Progression-Free
Survival or Median
Time to Progression
Median Overall
Survival Months
BREAK-MB
Long et al. 20125,32
Dabrafenib None II Cohort A (no prior treatment): 74
Cohort B (prior treatment): 65
39 (2 CR, 27 PR)
31 (0 CR, 20 PR)
6.3 mo (A) and 4.5
mo (B)
13.1 (A) and
12.9 (B)
Mornex et al. 200333 Fotemustine + WBRT 37.5 Gy in
15 fractions
III 37 10 – 2.9 (NS)
Margolin et al. 20124 Ipilimumab None II Cohort A (without corticosteroids): 51
Cohort B (with corticosteroids): 21
10 (5 PR)
5 (1 PR)
– 7 (A) and 4 (B)
NIBIT-M1
Di Giacomo et al. 201234
Ipilimumab + fotemustine None II 20 with asymptomatic brain mets 40 (2 irCR, 6 irPR) – –
Agarwala et al. 200414 Temozolomide None II 117 7 (1 CR, 7 PR) 1.2 mo 3.2
Hwu et al. 200535 Temozolomide + thalidomide None II 15 12 (2 CR, 1 PR) – 5
Atkins et al. 200836 Temozolomide + thalidomide + WBRT 30 Gy in 10
fractions
II 39 7.6 (1 CR, 2 PR) 1.8 mo 4
Margolin et al. 200237 Temozolomide + WBRT 30 Gy in 10
fractions
I/II 31 9.7 (1 CR, 2 PR) 2 mo 6
irCR, immune-related complete response; irPR, immune-related partial response; CR, complete response; PR, partial response; (NS), not significant; WBRT, whole brain radiotherapy.
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dabrafenib in BRAF-mutated tumors and smaller studies with
ipilimumab have demonstrated improved intracranial response
rates, especially compared with conventional chemotherapies
(Table 1), the cornerstone of treatment for melanoma brain
metastases is radiation therapy (RT). In general, whole brain
radiotherapy (WBRT) is administered for multiple brain metastases
(≥3-4 lesions), whereas stereotactic radiosurgery (SRS) is adminis-
tered for nonresectable single or oligometastases. To date, no reported
randomized clinical trials of WBRT or SRS have been conducted for
brain metastases from melanoma. A randomized phase III study
evaluating the benefit of WBRT versus observation following local
treatment of melanoma brain metastases is currently under way [9].
In addition, no randomized clinical trials have been reported with
WBRT or SRS in patients with four or more metastatic lesions to the
brain. However, melanoma is a particularly radioresistant tumor,
leading some authors to question the benefit of low-dose WBRT [10],
in addition to the known neurocognitive sequelae of treatment [11].
Given the relative radioresistance of the disease [6,12], intensification
of radiation treatment with radiosensitizing agents is a logical
consideration [13,14]. To date, there have been no reports of a candidate
radiosensitizer that conclusively improves outcomes of patients with brain
metastases from melanoma or any solid tumor histology.
A new agent under investigation, RRx-001, demonstrates evidence
of antitumor effect in patients with a wide variety of malignancies,
including melanoma. RRx-001 is a small molecule sourced from the
aerospace industry with a novel chemical structure (Figure 1). It is
under investigation as a single agent, chemosensitizer, and radio-
sensitizer in several clinical trials. RRx-001 mediates an increase of
tumor blood flow and subsequent oxygenation in tumors, which may
enhance radiosensitization [15,16]. The mechanism is, at least in part,
nitric oxide (NO) related. Under hypoxic conditions, NO production
via constitutive nitric oxide synthase (NOS) enzymes is decreased,
with a resultant increase in deoxyhemoglobin-mediation NOFigure 1. Chemical structure of RRx-001.production, which converts nitrite (NO2
−) to NO. RRx-001, which
binds to hemoglobin, greatly accelerates the NO2
− to NO conversion
of deoxyhemoglobin (Figure 2) [17,18]: the result is that, unlike other
nitric oxide donors (e.g., nitroglycerine), NO acts locally, not
systemically, and especially under hypoxic conditions such as in
primary tumors and metastases [19]. The radiosensitizing effects of
nitric oxide are attributable to multiple factors including vasodilation,
vascular stabilization, and inhibition of DNA repair enzymes [20].
This report describes the initial two patients with adequate
follow-up treated on BRAINSTORM, a phase 1/2 dose-escalation
clinical trial of RRx-001 in combination with WBRT in patients with
solid tumor brain metastases. Both patients responded at the lowest
dose level of 5 mg/m2 in the absence of neurologic toxicity.
Results
Case 1
A 62-year-old white man was initially diagnosed with cutaneous
melanoma of the left arm for which he underwent wide local excision
and sentinel lymph node biopsy, demonstrating melanoma (nodular
type, Breslow depth 3.5 mmwithout ulceration) and one of five lymph
nodes positive. Completion axillary lymph node dissection revealed no
further disease. He presented 3 years later with biopsy-proven
recurrence in the left axilla. Staging workup revealed no other sites of
disease. He underwent reoperative axillary lymph node dissection,
which demonstrated melanoma involving the subcutaneous tissue
(measuring 2 cm in greatest diameter), and seven lymph nodes negative
for neoplasm. The patient underwent adjuvant axillary radiation and
did well until 5 months later when he developed new-onset cough with
a computed tomography of the chest revealing new pulmonary nodules
measuring up to 1.9 cm, confirmed by biopsy to be melanoma, as well
as soft tissue nodules in the anterior abdomen.
Soon thereafter, the patient noted decreased visual acuity and
central and right-sided visual field deficit. Brain magnetic resonance
imaging (MRI) revealed the presence of a 2.2 × 2.6 × 2.6–cm mass
in the left occipital lobe and a 3.3 × 2.7 × 2.2–cm mass in the right
occipital lobe, as well as three other supratentorial lesions. All lesions
were hemorrhagic with surrounding vasogenic edema. Dexametha-
sone 4 mg TID was started without improvement in symptoms. The
patient was enrolled on clinical trial and received a single peripheral
intravenous dose of RRx-001 (5 mg/m2) 4 days before the initiation
of WBRT. Twenty-four hours after the first dose of RRx-001,
Figure 2. After injection in the bloodstream, RRx-001 penetrates the red cell membrane and binds to a specific residue on hemoglobin.
These RRx-001–modified red blood cells home to the hypoxic tumor vasculature. Under hypoxic conditions common to tumors, RRx-001
accelerates deoxyhemoglobin-mediated NO production.
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decrease in ktrans in four of five lesions, suggesting a reduction in
vessel leakiness after exposure to the drug. He was then treated with
RRx-001 at 5 mg/m2 in combination with WBRT (30 Gy in 10
fractions). Within 48 hours, the patient’s visual symptoms began to
improve. RRx-001 was well-tolerated with mild, transient infusion
site pain and without any signs of systemic or neurologic toxicity. By
the end of treatment, the patient reported improved visual symptoms
with near resolution of visual field deficit, and dexamethasone was
tapered following completion of WRBT. Four weeks after the
completion of RRx-001 and WBRT, a contrasted brain MRI
confirmed a decrease in the size of the largest left and right occipital
masses and evolving hemorrhagic change in the other three lesions
consistent with resolving hemorrhage. The patient reported full
physical function with no impairment of activities of daily living, asFigure 3. Left panel is a representative axial image from a T1 gadol
occipital lesion before treatment. Middle panel demonstrates marked
RRx-001, which was accompanied by resolution of the visual field
4 months after WBRT plus RRx-001.reported by the Barthel ADL Index, which was unchanged from
baseline. Self-reported quality of life using the Functional Assessment
of Cancer Therapy instrument revealed stability in all four reported
subscales (physical, social, emotional, and functional) 1 month after
treatment compared with baseline. Four months after completion of
treatment, continued response was seen in all evaluable lesions (left
occipital lobe lesion now measuring 0.9 × 0.6 × 1.0 cm and right
occipital lobe lesion measuring 2.3 × 2.2 × 1.5 cm), in addition to a
decrease in associated edema of all lesions that were also improved
compared with before (Figure 3). A new 5-mm lesion was discovered
at 4 months, possibly from seeding due to persistent systemic disease.
Case 2
The second patient was a 40-year-old white man initially diagnosed
with a melanoma of the upper back 5 years ago (Clark level IV,inium-enhanced brain MRI of the patient’s most symptomatic left
response of the lesion 1 month following 2 weeks of WBRT plus
deficits. Right panel demonstrates further response of the lesion
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underwent wide local excision and sentinel lymph node biopsy
with axillary dissection of the right and left axilla, revealing 1 of 21
lymph nodes and 1 of 18 lymph nodes involved, respectively. He
elected to undergo surveillance and remained disease free until 5 years
later when he developed progressive right arm pain. Restaging
confirmed recurrent metastases involving the superior mediastinum,
multiple subcutaneous sites, retroperitoneal adenopathy, and at least
18 new asymptomatic brain metastases, most measuring 2 to 3 mm
with the largest, partially hemorrhagic lesion measuring 1.7 cm. He
was enrolled on study and received RRx-001 (5 mg/m2) 4 days
before WBRT, followed by 2 weeks of WBRT and twice weekly
RRx-001 at the same dose, per protocol. Twenty-four hours after
administration of the drug, a slight reduction in ktrans was noted in
the largest evaluable lesion. Subcentimeter lesions could not be
quantitatively evaluated with DCE-MRI because of their small size.
He had no significant infusion site pain during treatment. At
1 month posttreatment, no significant change in the lesions was seen.
The patient reported full physical function and ability to perform
activities of daily living 1 month after the end of treatment (as
measured by the Barthel ADL index), which was unchanged from
baseline. He had no new neurologic symptoms. Self-reported quality
of life using Functional Assessment of Cancer Therapy demonstrated
decline in the four measured subscales 1 month after treatment in the
setting of progressive systemic disease. Serial brain reimaging revealed
partial response intracranially 3 months after treatment, with
disappearance of three lesions and shrinkage in all other lesions.
Four months after the end of treatment, marked response was seen in
the brain, confirming the findings at 3 months, with complete
disappearance of all but 5 of the initial 18 visualized lesions and size
reduction in the remaining 5 (Figure 4).
Discussion
Poor outcomes among patients with brain metastases, with an overall
median survival of 1 to 2 months without treatment and 3 to
8 months with treatment, have led to their exclusion from most
clinical trials, making this a relatively understudied patient population
[21–23]. Despite the relative radioresistance of melanoma [24,25],
RT remains the primary treatment option due to the failure of
systemic chemotherapy to control or prevent brain metastases, which
shelter behind the sanctuary of the Blood Brain Barrier (BBB) [26].Figure 4. Left panel is a representative image from a T1 gadolinium-en
metastasis before treatment. Middle panel demonstrates the appeara
is not significantly changed in size. Right panel demonstrates compleFor example, the response rates of temozolomide in the brain are less
than 10% (Table 1). Although emerging data from retrospective
studies suggest that stereotactic radiosurgery is effective in combina-
tion with checkpoint inhibitors in brain metastases [27] from
multiple tumor types, and newer molecular agents such as the BRAF
inhibitor dabrafenib are associated with higher response rates and
better survival (Table 1), prospective studies are required to evaluate
whether these new regimens are comparable or superior to WBRT.
BRAINSTORM is a phase I/II dose escalation study of IV
RRx-001, a novel, systemically nontoxic agent with evidence of
chemo- and radiosensitizing properties [28], administered twice
weekly for 2 weeks in combination with WBRT (30 Gy in 10
fractions), with the option to continue RRx-001 once weekly as
maintenance after WBRT (Figure 5).
The primary end point of the trial is to determine the maximum
tolerated dose of RRx-001 in combination with WBRT. Secondary
end points include best overall response rate, intracranial progres-
sion-free and overall survival, as well as measurement of neurocog-
nitive status and tumor blood flow with serial DCE-MR imaging.
This report demonstrates the radiosensitization potential of
RRx-001 even at the lowest dose of twice weekly 5 mg/m2 in the
first and third patients with brain metastases treated on the
BRAINSTORM clinical trial. The second patient with metastatic
melanoma died unexpectedly before response could be assessed with
adequate follow-up, possibly because of an acute, unrelated
cardiopulmonary event. Treatment for the two patients with adequate
follow-up was well tolerated, with mild transient localized infusion
pain as the only adverse event. In addition, patients reported complete
maintenance of their physical function before and after treatment.
The observed enhanced radiation response, resulting in neurological
improvement and significant tumor shrinkage at 3- and 4-month
assessments, may correlate with the RRx-001–induced increase in
tumor blood flow and, by extrapolation, tumor oxygenation. The
relationship between tumor perfusion and radiosensitization will be
further evaluated on this trial via serial perfusion MRI.
Radiation sensitivity is significantly enhanced in the presence of
oxygen. Cells that are anoxic during irradiation are only about one
third as sensitive to its cytotoxic effects as their oxygenated
counterparts [29,30]; hypoxia is therefore associated with an
increased risk of disease recurrence [31]. However, over the last
four to five decades, hypoxia-targeted therapies that locally orhanced brain MRI demonstrating a subcentimeter enhancing brain
nce of the lesion 1 month after the end of WBRT + RRx-001, which
te disappearance of the lesion 4 months after the end of treatment.
Figure 5. BRAINSTORM phase I/II study schema.
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pretreatment transfusion, hyperfractionation, carbogen breathing, and
electron-affinic and hypoxic-cell sensitizers together with RT consis-
tently have failed to demonstrate a significant benefit [6,12].
By contrast, this report suggests that RRx-001, at the lowest dose of
5 mg/m2 administered twice weekly, is safe as expected and active
when used with WBRT for melanoma brain metastases.
In conclusion, RRx-001 is a well-tolerated agent with radiosensitizing
potential that may improve clinical outcomes in patients with
metastases from melanoma and other cancers. The partial responses
and the promising findings from advanced neuroimaging from these
two patients heighten interest in further investigation of RRx-001 with
dose escalation as planned in the BRAINSTORM trial.
Experimental Procedures
The two cases reported in this article were observed in the ongoing phase
I/II clinical trial BRAINSTORM (clinical trial registration identifier,
NCT02215512). The methods in this study were carried out in
accordance with approved guidelines. The necessary informed consents
were obtained. The relevant Institutional Review Boards at University of
Michigan Medical School approved all experimental protocols.
Patients with pathologic confirmation of a solid tumor malignancy
and a clinical history consistent with metastatic disease to the brain
that can be imaged by MRI, with adequate laboratory values; an
ECOG score of 0 to 2 (Eastern Cooperative Oncology Group
Performance Status); an estimated life expectancy of at least 12 weeks;
and discontinuation of systemic chemotherapy, other biologic
therapy, or investigational agent at least 2 weeks before intervention
were recruited onto this dose escalation study at the University of
Michigan to receive one of four dose levels of RRx-001 (5, 8.4, 16.5,
and 27.5 mg/m2 twice weekly) in combination withWBRT. Patients
received intravenous RRx-001 4 days before WBRT (30 Gy in 10
daily fractions), then twice weekly during WBRT for 5 total doses.
The patients described in this report received an RRx-001 dose of5 mg/m2 twice weekly. Patients underwent DCE-MRI pretreatment,
24 hours after RRx-001 before WBRT, just before the last fraction of
WBRT + RRx-001, and 1 month and 4 months after WBRT.
Quantitative imaging parameters including mean ktrans and tumor size
were analyzed at each time point. Patients were followed serially with
neurologic and functional assessments, and dose-limiting toxicity was
evaluated within the 28 days following completion of treatment.
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